Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000951898 | SCV001098349 | likely benign | not provided | 2022-08-11 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002489306 | SCV002798834 | likely benign | Epilepsy, idiopathic generalized, susceptibility to, 11; Familial hyperaldosteronism type II; Leukoencephalopathy with mild cerebellar ataxia and white matter edema | 2021-07-14 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003169468 | SCV003874348 | uncertain significance | Inborn genetic diseases | 2023-02-28 | criteria provided, single submitter | clinical testing | The c.1141C>G (p.P381A) alteration is located in exon 11 (coding exon 11) of the CLCN2 gene. This alteration results from a C to G substitution at nucleotide position 1141, causing the proline (P) at amino acid position 381 to be replaced by an alanine (A). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
School Of Forensic, |
RCV004720285 | SCV004805641 | likely pathogenic | Epilepsy, idiopathic generalized, susceptibility to, 11 | no assertion criteria provided | research |